Another study has shown the beneficial effects of SFK inhibitors for the treatment of AML patients carrying co-occurring FLT3-ITD and NUP98-NSD1 mutations, which is among the most unfavorable AML forms associated with poor prognosis [97]. The gene discussed is FLT3; the disease is acute myeloid leukemia.